• Home
  • Resource Library

Resource Library

publications • bibliographies • white papers

All Publications

  • Are metformin, statin and aspirin use still associated with overall mortality among colorectal cancer patients with diabetes if adjusted for one another?Abstract

    BACKGROUND: Metformin, statin and aspirin use seem associated with decreased mortality in cancer patients, though, without adjusting for one another. Independent associations of these drugs with overall mortality after colorectal cancer (CRC) diagnsis within glucose-lowering drugs (GLDs) users were assessed

    Zander s MM, van Herk-Sukel MP, Vissers PA, Herings RM, Haak HR, van dePoll-Franse LV. Br J Cancer. 2015 Jul 28; 113 (3): 403-10.
  • Long-term persistence with anti-osteoporosis drugs after fractureAbstract

    Long-term persistence with anti-osteoporosis drugs and determinants for discontinuation among fracture patients were examined. Persistence was 75.0 and 45.3 % after 1 and 5 years, respectively. Those aged >/=80 years were at increased risk of earlydiscontinuation. Within 1 year after discontinuation, 24

    Klop C, Welsing PM, Elder s PJ, Overbeek JA, Souverein PC, Burden AM, van Onzenoort HA, Leufkens HG, Bijlsma JW, deVries F. Osteoporos Int. 2015 Jun; 26 (6): 1831-40.
  • Impact of cancer on adherence to glucose-lowering drug treatment in individuals with diabetesAbstract

    AIMS/HYPOTHESIS: Adherence to glucose-lowering drug (GLD) treatment regimens is crucial for metabolic control and improving prognosis. Because a diagnosis of cancer might have an impact on adherence to medication, this study explored changes in adhrence to GLDs following a cancer diagnosis. METHODS: All new users of GLDs between 1998 and 2011 who lived in the Eindhoven Cancer Registry-PHARMO Database Network catchment area were selected

    Zander s MM, Haak HR, van Herk-Sukel MP, van dePoll-Franse LV, Johnson JA. Diabetologia. 2015 May; 58 (5): 951-60.
  • Quick assessment of drug-related admissions over time (QUADRAT study)Abstract

    PURPOSE: To develop a computerized prescreening procedure for the identification of possible/probably Hospital Admissions potential Related to Medications (HARMs). METHOD: Pairs of drugs and reasons for hospitalization (generated automatically fromthe PHARMO record linkage database by using two data mining techniques) were assessed manually to determine whether they represented pharmacologically plausible adverse drug events (PP-ADEs)

    Warle-van Herwaarden MF, Valkhoff VE, Herings RM, Engelkes M, van Blijder veen JC, Roden burg EM, deBie S, Alsma J, van deSteeg-Gompel C, Kramers C, Meyboom RH, Sturkenboom MC, DeSmet PA. Pharmacoepidemiol Drug Saf. 2015 May; 24 (5): 495-503.
  • Burden of Exacerbations in Patients with Moderate to Very Severe COPD in the Netherlands: A Real-life StudyAbstract

    OBJECTIVE: The objective of this study was to compare rates of different types of acute exacerbations of COPD (AECOPDs) and healthcare utilization among patients with different severities of COPD. METHODS: Data for this study was obtained from theHARMO Database Network, which includes drug dispensing records from pharmacies, hospitalization records and information from general practitioners

    Overbeek JA, Penning-van Beest FJ, Balp MM, Dekhuijzen PN, Herings RM. COPD. 2015 Apr; 12 (2): 132-43.
  • Treatment with rivastigmine or galantamine and risk of urinary incontinence: results from a Dutch database studyAbstract

    BACKGROUND: Treatment of Alzheimer disease (AD) with cholinesterase inhibitors (ChEIs) may increase the risk of urinary incontinence (UI). OBJECTIVE: To assess whether ChEI use was associated with the risk of UI among older patients with AD. METHOD: A crossover cohort study using the PHARMO Record Linkage System included 10 years of data on drug dispensing histories for over two million Dutch residents

    Kroger E, VanMarum R, Souverein P, Carmichael PH, Egberts T. Pharmacoepidemiol Drug Saf. 2015 Mar; 24 (3): 276-85.
  • High daily insulin exposure in patients with type 2 diabetes is associated with increased risk of cardiovascular eventsAbstract

    AIMS: Intensive glucose control, often involving insulin treatment, failed to improve cardiovascular outcomes in several clinical trials. Observational studies reported an association between insulin use and cardiovascular disease (CVD) risk. It hatherefore been suggested that insulin adversely affects CVD risk

    Stoekenbroek RM, Rensing KL, BernelotMoens SJ, Nieuwdorp M, DeVries JH, Zwinder man AH, Stroes ES, Currie CJ, Hutten BA. Atherosclerosis. 2015 Mar 30; 240 (2): 318-323.
  • Healthcare utilisation in patients with breast cancer or non-Hodgkin lymphoma who experienced febrile neutropenia in the Netherlands: a retrospective matched control study using the PHARMO databaseAbstract

    Few data have been published on healthcare resource utilisation associated with chemotherapy-induced febrile neutropenia (FN) in Europe. Using the PHARMO record linkage system, we identified incident adult patients with a primary hospital dischargediagnosis of breast cancer (BC) or non-Hodgkin lymphoma (NHL) from 1998 to 2008

    Issa DE, Gelder blom H, Lugtenburg PJ, van Herk-Sukel MP, Houweling LM, DeLaOrden M, van der Werf-Langenberg ME, Nortier JW, deJong FA. Eur J Cancer Care (Engl). 2015 Mar; 24 (2): 232-41.
  • Evaluating performance of electronic healthcare records and spontaneous reporting data in drug safety signal detectionAbstract

    Background Electronic reporting and processing of suspected adverse drug reactions (ADRs) is increasing and has facilitated automated screening procedures. It is crucial for healthcare professionals to understand the nature and proper use of data aailable in pharmacovigilance practice. Objectives To (a) compare performance of EU-ADR [electronic healthcare record (EHR) exemplar] and FAERS [spontaneous reporting system (SRS) exemplar] databases in detecting signals using “positive” and “negative” drug-event reference sets; and (b) evaluate the impact of timing bias on sensitivity thresholds by comparing all data to data restricted to the time before a warning/regulatory action

    Patadia VK, Schuemie MJ, Coloma P, Herings R, van der Lei J, Straus S, Sturkenboom M, Trifiro G. Int J Clin Pharm. 2015 Feb; 37 (1): 94-104.
  • Using real-world healthcare data for pharmacovigilance signal detection – the experience of the EU-ADR projectAbstract

    A prospective pharmacovigilance signal detection study, comparing the real-world healthcare data (EU-ADR) and two spontaneous reporting system (SRS) databases, US FDA’s Adverse Event Reporting System and WHO’s Vigibase is reported. The study compard drug safety signals found in the EU-ADR and SRS databases

    Patadia VK, Coloma P, Schuemie MJ, Herings R, Gini R, Mazzaglia G, Picelli G, Fornari C, Peder sen L, van der Lei J, Sturkenboom M, Trifiro G, consortium Eu-Adr. Expert Rev Clin Pharmacol. 2015 Jan; 8 (1): 95-102.